Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-07-12
2011-07-12
Reddig, Peter J (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387700, C530S387900, C530S388100, C530S388800, C530S388850, C530S389100, C530S389700
Reexamination Certificate
active
07977462
ABSTRACT:
The invention discloses 482 novel phosphorylation sites identified in carcinoma and/or leukemia, peptides (including AQUA peptides) comprising a phosphorylation site of the invention, antibodies specifically bind to a novel phosphorylation site of the invention, and diagnostic and therapeutic uses of the above.
REFERENCES:
patent: 3940475 (1976-02-01), Gross et al.
patent: 4289747 (1981-09-01), Chu et al.
patent: 4349893 (1982-09-01), Wiegman et al.
patent: 4376110 (1983-03-01), David et al.
patent: 4474893 (1984-10-01), Reading et al.
patent: 4634664 (1987-01-01), Oestberg et al.
patent: 4634666 (1987-01-01), Engleman et al.
patent: 4659678 (1987-04-01), Forrest et al.
patent: 4676980 (1987-06-01), Segal et al.
patent: 4727022 (1988-02-01), Skold et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4946778 (1990-08-01), Ladner et al.
patent: 5004692 (1991-04-01), Tso et al.
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5112946 (1992-05-01), Maione et al.
patent: 5192744 (1993-03-01), Bouck et al.
patent: 5202352 (1993-04-01), Okada et al.
patent: 5225539 (1993-07-01), Winter et al.
patent: 5260203 (1993-11-01), Ladner et al.
patent: 5530101 (1996-06-01), Queen et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5675063 (1997-10-01), Knight et al.
patent: 5677427 (1997-10-01), Goldenberg et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5789208 (1998-08-01), Sharon et al.
patent: 5969108 (1999-10-01), McCafferty et al.
patent: 6103889 (2000-08-01), Whitlow et al.
patent: 6120767 (2000-09-01), Robinson et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6329508 (2001-12-01), Friden et al.
patent: 6331415 (2001-12-01), Cabilly et al.
patent: 6335163 (2002-01-01), Sharon et al.
patent: 6355245 (2002-03-01), Evans et al.
patent: 6395718 (2002-05-01), Slusher et al.
patent: 6407213 (2002-06-01), Carter et al.
patent: 6441140 (2002-08-01), Comb et al.
patent: 6462075 (2002-10-01), Bowen et al.
patent: 6465431 (2002-10-01), Thorn et al.
patent: 6475784 (2002-11-01), Papkoff et al.
patent: 6482802 (2002-11-01), Hu et al.
patent: 6482810 (2002-11-01), Brem et al.
patent: 6500431 (2002-12-01), Gill et al.
patent: 6500924 (2002-12-01), Brooks et al.
patent: 6518298 (2003-02-01), Green et al.
patent: 6521439 (2003-02-01), Folkman et al.
patent: 6525019 (2003-02-01), D'Amato et al.
patent: 6538103 (2003-03-01), Ji et al.
patent: 6544758 (2003-04-01), O'Reilly et al.
patent: 6544947 (2003-04-01), Holaday et al.
patent: 6548477 (2003-04-01), Olson et al.
patent: 6548640 (2003-04-01), Winter et al.
patent: 6559126 (2003-05-01), Tournaire et al.
patent: 6569845 (2003-05-01), Futamura et al.
patent: 6573256 (2003-06-01), Bishop et al.
patent: 6783961 (2004-08-01), Edwards et al.
patent: 6867007 (2005-03-01), Kauvar et al.
patent: 6884869 (2005-04-01), Senter et al.
patent: 6979557 (2005-12-01), Isogai et al.
patent: 7109000 (2006-09-01), Edinger et al.
patent: 7198896 (2007-04-01), Rush et al.
patent: 7300753 (2007-11-01), Rush et al.
patent: 0120694 (1984-03-01), None
patent: 1184665 (1986-09-01), None
patent: 0239400 (1987-09-01), None
patent: 0404097 (1990-12-01), None
patent: WO 84/03508 (1984-09-01), None
patent: WO 85/03508 (1985-08-01), None
patent: WO 86/01533 (1986-03-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 91/17271 (1991-11-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 93/11161 (1993-06-01), None
patent: WO 93/12227 (1993-06-01), None
patent: WO 95/20401 (1995-08-01), None
patent: WO 96/27011 (1996-06-01), None
patent: WO 00/49144 (2000-08-01), None
patent: WO 02/00729 (2002-03-01), None
patent: WO 03/016861 (2003-02-01), None
patent: WO 03/089474 (2003-10-01), None
patent: WO 03/106644 (2003-12-01), None
patent: WO 2004/009618 (2004-01-01), None
patent: WO 2004/039963 (2004-05-01), None
patent: WO 2004/066957 (2004-08-01), None
patent: WO 2004/091658 (2004-10-01), None
patent: WO 2005/056825 (2005-06-01), None
patent: WO 2005/083444 (2005-09-01), None
Andreev et al. (Mol. Cell. Biol. Mar. 1999 19: 2338-2350).
U.S. Appl. No. 10/634,581, filed May 8, 2003, Johnson et al.
Abu-Duhier et al., “Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukemia,” Br. J. Haematol. 113: 983-988 (2001).
Hardy, et al., “Clinical and Molecular Genetic Analysis of 19 Wolfram Syndrome Kindreds Demonstrating a Wide Spectrum of Mutations in WFS1,” Am. J. Hum. Genet. 65:1279-1290 (1999).
Dessein, et al., “Severe Hepatic Fibrosis inSchistoma mansoniInfection Is Controlled by a Major Locus That Is Closely Linked to the Interferon-y Receptor Gene,” Am. J. Hum. Genet. 65: 709-721 (1999).
Di Barletta, et al., “Different Mutations in the LMNA Gene Cause Autosomal Dominant and Autosomal Recessive Emery-Dreifuss Muscular Dystrophy,” Am. J. Hum. Genet. 66:1407-1412 (2000).
Ebrahimi, et al., “Murine Gammaherpesvirus-68 Infection Causes Multi-Organ Fibrosis and Alters Leukocyte Trafficking in Interferon-y Receptor Knockout Mice,” American Journal of Pathology, 158(6): 2117-2125 (Jun. 2001).
Jemal, et al., “Cancer Statistics 2005,” CA: A Cancer Journal for Clinicians, 55(1): 10-30 (Jan./Feb. 2005).
Pollard, et al., “Using Single-Gene Deletions to Identify Checkpoints in the Progression of Systemic Autoimmunity,” Annals of the New York Academy of Sciences 987: 236-239 (Apr. 2003).
Jaskiewicz, et al., “Expression of p53 Tumor Suppressor Gene, Oncoprotein c-erbB-2, Cellular Proliferation and Differentiation n Malignant and Benign Pancreatic Lesions,” Anticancer Research 14: 1919-1922 (1994).
Agarwal, et al., “Inositol Hexaphosphate Inhibits Constitutive Activation of NF-xB in Androgen-independent Human Prostate Carcinoma DU145 Cells,” Anticancer Research 23: 3855-3862 (2003).
Arias-Romero, et al., “A tale of two Paks,” Biol. Cell 100: 97-108 (2008).
Bache, et al., “Phosphorylation of Hrs downstream of the epidermal growth factor receptor,” Eur. J. Biochem 269: 3881-3881 (2002).
Belsches, et al., “Role of c-Src Tyrosine Kinase in EEGF-Induced Mitogenesis,” Frontiers in Bioscience 269: 3881-3887 (Oct. 15, 1997).
G-Amlak, et al., “Reguation of myeloma cell growth through Akt/Gsk3/forkhead signaling pathway,” Biochemical and Biophysical Research Sommunications 297: 760-764 (2002).
Radaeva, et al., “Interferon-y inhibits interferon-a signalling in hepatic cells: evidence for the involvement of STAT1 induction and hyperexpression of STAT1 in chronic hepatitis C,” Biochem J. 379: 199-208 (2004).
Awasthi, et al., “Novel Function of Human RLIP76: ATP-Dependent Transport of Glutathione Conjugates and Doxorubicin”, Biochemistry 39: 9327-9334 (2000).
Jagani, et al., “Foxe tumor suppressors and BCR-ABL-induced leukemia: A matter of evasion of apoptosis,” Biochimica et Biophysica Acta 1785: 63-84 (2008).
Hashimoto, et al., “The Breakpoint Cluster Region Gene on Chromosome 22q11 Is Associated with Bipolar Disorder,” Biol Psychiatry 57(10): 1097-1102 (May 15, 2005).
Bird, et al., “Single-Chain Antigen-Binding Proteins,” Science 242: 423-426 (Oct. 21, 1988).
Blood, et al., “Tumor interactions with the vasculature: angiogenesis and tumor metastasis,” Biochemica et Biophysica Acta 1032: 89-118 (1990).
Awasthi, et al., “RLIP76, a non-ABC transporter, and drug resistance in epilepsy,” BMC Neuroscience 6(61): 1-11 (2005).
Boder, et al., “Yeast surface display for screening combinatorial polypeptide libraries” , Nature Biotechnology 15: 553-557 (Jun. 1997).
Bordin, et al., “Band 3 is an anchor protein and a target for SHP-2 tyrosine phosphatase in human erythrocytes,” Blood 100(1): 276-282 (Jul. 1, 2002).
Brand, et al., “Fluor
Cherry Jessica
Farnsworth Charles
Goss Valerie
Gu Ting-Lei
Guo Ailan
Cell Signaling Technology, Inc.
Reddig Peter J
Wilker Nancy Chiu
LandOfFree
Tyrosine phosphorylation sites does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tyrosine phosphorylation sites, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tyrosine phosphorylation sites will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2736616